MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Publication rates and characteristics of clinical trials in deep brain and responsive neurostimulation

M. Chua, A. Warren, J. Rolston (Boston, USA)

Meeting: 2023 International Congress

Abstract Number: 612

Keywords: Deep brain stimulation (DBS), Implanted pulse generators(IPG)

Category: Epidemiology

Objective: We examine DBS and RNS trials from 1997-2022, chart their characteristics, and examine rates and predictors of results reporting.

Background: Prompt dissemination of clinical trial results is essential for ensuring the safety and efficacy of deep brain stimulation (DBS) and responsive neurostimulation (RNS). However, the frequency and completeness of results publication are unknown. Moreover, the patient populations, targeted anatomical locations, and stimulation parameters should be clearly reported for both reproducibility and to identify lacunae in trial design

Method: Trials were identified using ClinicalTrials.gov. Associated publications were identified using ClinicalTrials.gov and PubMed.gov. Pearson’s Chi-squared tests were used to assess differences in trial characteristics between published and unpublished trials.

Results: Across 449 trials, representing a cumulative cohort of 42,769 patient interventions, there were 37 therapeutic indications and 44 stimulation targets. The most common indication and target were Parkinson’s Disease (40.55%) and subthalamic nucleus (35.88%), respectively. Only 0.89% of trials were in pediatric patients (11.58% were mixed pediatric and adult). Explored targets represented 75% of potential basal ganglia targets, but only 29% of potential thalamic targets. Allowing a 1-year grace period after trial completion, 34/169 (20.12%) had results reported on ClinicalTrials.gov and 107/169 (63.31%) were published. ~80% of published trials included details about stimulation parameters used. Published and unpublished trials did not significantly differ by trial characteristics.

Conclusion: We highlight key knowledge and performance gaps in DBS and RNS trial research. Over one-third of trials remain unpublished >1 year after completion; pediatric trials are scarce; most of the thalamus remains unexplored; about one-in-five trials fail to report stimulation parameters; and movement disorders comprise the most studied indications.

Figures

Figures2

Figures3

To cite this abstract in AMA style:

M. Chua, A. Warren, J. Rolston. Publication rates and characteristics of clinical trials in deep brain and responsive neurostimulation [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/publication-rates-and-characteristics-of-clinical-trials-in-deep-brain-and-responsive-neurostimulation/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/publication-rates-and-characteristics-of-clinical-trials-in-deep-brain-and-responsive-neurostimulation/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley